Screening designs for drug development

19Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We propose drug screening designs based on a Bayesian decision-theoretic approach. The discussion is motivated by screening designs for phase II studies. The proposed screening designs allow consideration of multiple treatments simultaneously. In each period, new treatments can arise and currently considered treatments can be dropped. Once a treatment is removed from the phase II screening trial, a terminal decision is made about abandoning the treatment or recommending it for a future confirmatory phase III study. The decision about dropping treatments from the active set is a sequential stopping decision. We propose a solution based on decision boundaries in the space of marginal posterior moments for the unknown parameter of interest that relates to each treatment. We present a Monte Carlo simulation algorithm to implement the proposed approach. We provide an implementation of the proposed method as an easy to use R library available for public domain download (http://www.stat. rice.edu/~rusi/ or http://odin.mdacc.tmc.edu/~pm/). © 2006 The Authors.

Cite

CITATION STYLE

APA

Rossell, D., Müller, P., & Rosner, G. L. (2007). Screening designs for drug development. Biostatistics, 8(3), 595–608. https://doi.org/10.1093/biostatistics/kxl031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free